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Introduction
Over the last two decades, cancer diagnostics in the era of pre-
cision or personalized medicine has made tremendous headway 
with the recent advances in science and technology making it 
possible for early detection as well as non-invasive or mini-
mally invasive monitoring, using liquid biopsies. Early detec-
tion and molecular characterization of tumors is crucial to a 
positive prognostic outcome by guiding therapeutic decisions. 
The current standard of care in genotyping solid tumor tissue 
for cancer patients to identify somatic gene variants for thera-
peutic action primarily begins with an invasive surgical biopsy 
procedure, limiting the longitudinal follow-up. In contrast, liq-
uid biopsies being minimally invasive allow for evaluation of 
the patient at multiple time points during and post-therapy to 
assess treatment response as well as for the detection of recur-
rence, resistance, and minimal residual disease, in theory ena-
bling timely interventions as deemed necessary for effective 
management of disease. They also offset the burden of a surgi-
cal biopsy and are extremely valuable in cases where a patient is 
diagnosed with an inoperable/inaccessible tumor or primary 
biopsy of tissue is not possible due to high risk of bleeding or 
nerve injury.1
Depending on the cancer type and stage, a number of speci-
mens such as blood (plasma, serum), urine, saliva, pleural effu-
sions, amniotic fluid, nasal secretions, bronchoalveolar lavages, 
lymphatic and peritoneal fluids, bone marrow aspirates, cerebro-
spinal fluid (CSF), prostatic fluid, peritoneal lavage, sputum, gas-
tric juice, breast milk, ascites and biliary, and even stool samples 
(Figure 1A) have been evaluated for their potential to serve as 
non-invasive surrogates of tumor monitoring,2 with plasma 
being preferred across all cancer types.3 CSF is preferred for 
tracking central nervous system (CNS) tumors4; saliva for head 
and neck cancers5; urine for renal cell carcinoma, bladder, and 
prostate cancer2; and stool being used for colorectal and pancre-
atic cancer.6 The main analytes being evaluated in liquid biopsies 
are extracellular vesicles (such as exosomes), circulating tumor 
cells (CTCs), and/or residual fragmented DNA3 (Figure 1B).
Exosomes are small round vesicles of endosomal origin, 
approximately 50-100 nm in diameter, carrying DNA, RNA, 
miRNAs, and proteins released by multiple cell types (includ-
ing tumor cells) into the extracellular environment.7 As genetic 
alterations promote the interphase of cancer cells, the cancer 
cells shed from the tumor as CTCs. As cells including CTCs 
undergo apoptosis, necrosis, and perhaps secretion,8–10 they 
shed fragmented DNA into the circulation. DNA released 
irrespective of cell of origin is called cell-free DNA (cfDNA), 
and when released specifically by cancer cells, it is referred to as 
circulating tumor DNA (ctDNA). Due to concerns of sensitiv-
ity and specificity, false negatives in particular, evaluation of 
CTCs is therefore not yet fully accepted into clinical practice 
for guiding treatment decisions.
cfDNA is a mixture of normal DNA, wild-type DNA from 
tumor, as well as mutated DNA from tumor, requiring high-
sensitivity technologies for detection, particularly since circu-
lating nucleic acids have variable circulating half-lives ranging 
from 15 minutes to several hours,11,12 with concentrations of 
0-1000 ng/mL of blood in cancer patients and 0-100 ng/mL of 
blood in healthy individuals.13,14 Analyzing cfDNA might not 
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provide information of the entire landscape of the tumor, espe-
cially keeping in mind tumor heterogeneity; however, if appro-
priate technologies are used, it does enable earlier detection 
with prognostic potential to a certain extent.15,16 Studies have 
demonstrated that serum has a 3-24 fold increase in cfDNA 
compared with plasma, as a result of hemolysis during clotting 
or from leukocyte contamination results, with the amount of 
contamination increasing with the number of days between 
blood withdrawal and serum separation.14,17 Increased cfDNA 
in serum is associated with a higher false positive rate, making 
plasma the preferred specimen for evaluation of cfDNA.
Evaluating the clinical utility of non-invasive techniques to 
detect molecular alterations in CTCs and cfDNA has been a 
topic of interest in precision oncology as it provides the poten-
tial to safely and cost-effectively monitor the tumor profile at 
multiple time points throughout the patient’s clinical course. 
This concept of longitudinal testing is made possible through 
the economics and practicality of easily accessible specimens 
such as blood, saliva, and urine. Furthermore, variable but posi-
tive evidence continues to emerge that demonstrates the poten-
tial benefit (and limitations) of capturing multiple observations 
of a tumor’s genomic profile over time.18 High-frequency mon-
itoring may also prove critical to a physician’s ability to tailor or 
change a therapeutic course based on the molecular evolution 
and diverse landscape of the tumor18; however, the ability of 
liquid biopsy tests to predict response to therapy is still the 
subject of active investigation in clinical and preclinical 
research. When tumors progress and metastasize, tumor sites 
may become inoperable. Obtaining a tissue sample that pro-
vides a landscape view of the tumor can become highly unlikely 
without the use of a liquid biopsy-based assay. Glioblastomas 
and spinal cancers can progress quickly, and obtaining a small 
tissue sample via a surgical biopsy may not provide a quick 
enough turnaround time at a chance to treat the cancer. Even a 
moderate amount of hemorrhage that occurs in the biopsy tract 
could be potentially threatening to the patient’s neurological 
function or even life.19 By implementing liquid biopsy tech-
nologies, a simple blood draw can provide real-time genetic 
and molecular information about the tumor without the inva-
sive surgical procedure which provides tremendous benefit to 
inoperable cancers such as brain and spinal cancers.20
The Current Landscape of Liquid Biopsy Testing
With personalized medicine increasingly expanding into the 
clinic, more therapeutics are actively being developed and used 
in patients based on the molecular profiles of their different 
cancer types which is why discovery and classification of these 
biomarkers is of utmost importance. Molecular evaluation of 
cfDNA in cancer patients has emerged as an attractive option 
offering multiple benefits in patients with diverse tumor types, 
with a highly precise evaluation of the tumor genomic altera-
tion landscape, reflective of disease burden.21–23
Clinical assays are developed to address an unmet need of the 
patient, are geared to a specific disease area, and use standard or 
novel technologies available in a specific lab. Detection of 
cfDNA requires highly sensitive techniques due to the small 
fraction of tumor-specific DNA mixed with wild-type cfDNA 
and some amount of genomic DNA from white blood cells. 
Standard methods for the detection of known hotspot mutations 
are polymerase chain reaction (PCR) based and include nested 
real-time PCR, mutant allele-specific PCR, and digital PCR 
which include droplet digital PCR (ddPCR), BEAMing, and 
microfluidic digital PCR.12 Targeted deep sequencing methods 
such as SafeSeq and CAPP-Seq are highly sensitive methods 
that allow for the detection of selected single nucleotide variants 
(SNVs), copy number variants (CNVs), and rearrangements 
across specific regions.12 Next-generation sequencing (NGS) 
technologies are currently being applied to cfDNA analysis, 
which enables high-throughput, low-cost sequencing to identify 
alterations genome wide, including estimation of tumor muta-
tion burden (TMB) and microsatellite instability (MSI).
Strategies for the evaluation of cfDNA depend on the end 
goal of identifying resistance, monitoring for minimal residual 
disease or prima facie looking for recurrence, to be able to 
implement appropriate treatment regimens or companion 
diagnostics as available. Toward that end, there are several tests 
currently available for clinical testing, ranging from hotspots in 
a single gene, full gene coverage, panels for specific cancers, or 
Figure 1. (A) Specimen types and (B) analytes for liquid biopsy.
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a combination of all the above (Table 1). The decidedly selec-
tive approach, often designed for the purpose of assessing 
highly recurrent loci for mutations that directly inform treat-
ment decisions through on-label use of Food and Drug 
Administration (FDA)-approved drugs or recommendations 
based on clinical practice guidelines, involves evaluation of hot-
spots or single genes. An example being the Cobas® EGFR 
Mutation Test v2 which is FDA approved for use in non-small 
cell lung cancer (NSCLC) patients. Focusing on evaluation of 
42 mutations in exons 18, 19, 20, and 21 in the EGFR gene, 
this test aims to help patients with NSCLC that may not be 
suitable to undergo an invasive procedure and a genetic test 
focusing on the EGFR gene alone may be beneficial for ther-
apy. An expanded approach for patients with an unknown pri-
mary tumor site would involve using a panel of genes such as 
the Guardant360 assay,24 which includes 73 genes in which all 
exons are completely sequenced to exploit the detection of 
known somatic variants. Similar to other tests currently avail-
able for clinical use that span the spectrum of hotspots, through 
single gene and/or encompass multiple genes (Table 1), this 
panel is used across different cancer types and specimens (blood 
and/or formalin fixed paraffin embedded-FFPE tissue) and 
can be used to identify multiple therapeutic targets.
Depending on the approach taken, there are associated 
advantages, limitations, and challenges. In terms of clinical util-
ity, single gene evaluation offers disease-specific coverage, a 
shorter turnaround time, is cost effective, and most importantly 
from a patient perspective, in the case of NSCLC as exemplified, 
is that the variants evaluated if detected are associated with tar-
geted therapies. However, there are also limitations with single 
gene assays, in terms of the potential to miss variants in other 
genes not being evaluated. The FDA-approved Cobas® EGFR 
Mutation Test v2 panel as outlined above targets specific EGFR 
mutations in NSCLC patients exclusively, missing other muta-
tions in genes such as ALK, BRAF, KRAS, MEK, and MET 
which also have potential to provide therapeutic yield.25 Another 
concern with such an approach is the observation that the fre-
quency of EGFR gene mutations in NSCLC patients when 
undergoing chemotherapy decreases26 and therefore although 
approved by the FDA, this assay may not represent a suitable test 
for monitoring NSCLC patients receiving chemotherapy.11,26 
When designing a single gene panel, identifying gene mutations 
with associated therapies is crucial but taking into consideration 
other factors that will impact a false-negative result is equally 
critical. While single gene panels offer a comprehensive view of 
the mutations that exist within that gene, significant data and 
information on the tumor can be lost without looking at possible 
mutations that may exist elsewhere and may be important for 
the treatment of the tumor.
Larger panels may not always be the best option in a clinical 
setting, as the cost increases and sequencing depth decreases per 
gene, the overall benefit to the patient can be uncertain but the 
greater potential to assess prognosis, detect recurrence, and get 
an insight into difficult-to-diagnose tumors remains present.11 T
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4 Biomarker Insights 
With a larger scope of genes to look at comes many variables and 
with that a multitude of challenges. In a recent cross-assay com-
parison, both the Guardant360 panel (Guardant Health Inc) 
and the PlasmaSELECT-R64 panel (Personal Genome 
Diagnostics) were run on identical metastatic prostate cancer 
patient samples to determine the reliability and potential utility 
of these assays.27 To determine concordance across both tests, 
only genetic alterations in genes supposedly covered by both 
platforms (42 genes) were considered. Patients with one or more 
alterations demonstrated by at least one platform (31 of 40), 
whose all cfDNA alterations were covered by only one of the 
tests, were excluded (6 of 40). Only 3 (7.5%) of the 40 patients 
had complete congruence with one or more alterations. There 
are a number of reasons for the lower concordance including 
small sample size, variation in genes evaluated (regions of cover-
age, depth of coverage, etc), timing of different samples collected, 
but most importantly differences in limit of detection (LOD). 
This study suggests that the lack of concordance in genetic pro-
filing across platforms and technologies could jeopardize the 
clinical benefit of personalized medicine. It also emphasizes that 
standardization of technologies and procedures across laborato-
ries is needed to ensure consistency of results.
Development and Validation of the JAX 
PlasmaMonitor™
To provide comprehensive monitoring of cancers, the Jackson 
Laboratory ( JAX) designed a non-invasive liquid biopsy assay to 
complement the current oncology test menu in the clinical labo-
ratory. The JAX PlasmaMonitorTM was developed to cater to our 
patient pool which primarily consists of stage IV metastatic can-
cers and was therefore developed as a pan cancer panel (Figure 2). 
Being able to use the PlasmaMonitorTM to track the progression 
of cancer, monitor any arising clones that may develop resistance 
to treatment therapy, as well as recognizing new possible thera-
pies as the tumor evolves is an undoubtable benefit. While main-
taining the highest of standards, the assay was to include the most 
clinically relevant genes across a wide scope of cancer types 
(Figure 2A-C) that could be provided to the clinician in a reason-
able amount of time, in a cost effective way, and was therefore 
designed to be a 14 gene, 84 variant hotspot pan cancer panel 
(Figure 2A).
To determine the coverage of the panel per cancer type, as 
an estimate of clinical utility, as the panel was designed, we 
used all the variants in catalog of somatic mutations in cancer 
(COSMIC) for each individual cancer type (such as breast 
cancer) to filter that list to contain only the variants present in 
the PlasmaMonitorTM for that tumor type. Data for the num-
ber of variants present in the panel identified for a specific gene 
in that tumor type and the number of samples mutated with 
those variants on our panel in a specific gene for that tumor 
type were narrowed down (Figure 2C). The goal was to provide 
an assay that could offset the disadvantages of a single gene and 
multi-gene panel while maintaining the benefits and integrity 
of what liquid biopsy panels are able to offer.
Panel design
To identify the most appropriate gene content for the panel, we 
scanned the literature to identify gene/variants with therapeu-
tic, prognostic, and/or diagnostic impact; evaluated the positive 
yield rate from our solid tumor NGS panels; and collated the 
information to design a panel primarily based on the actiona-
bility of variants (Figure 2D). Actionability being defined as 
evidence of response or resistance to FDA approved therapies 
and/or investigational therapies, availability clinical trials 
recruiting for a specific gene/variant, and evidence of prognos-
tic significance (Figure 2E). While the PlasmaMonitorTM is a 
smaller panel compared with some currently offered on the 
market (Table 1), it includes clinically relevant hotspot muta-
tions in genes across multiple cancer types (Figure 2A-C).
Technical considerations
As elucidated so far, while genomic profiling for tumor muta-
tions has been successfully demonstrated from cfDNA, the low 
amount of cfDNA in the blood, which can be less than 1% 
allelic frequency, presents significant challenges for reliable 
variant detection. As our NGS panel was developed, technical 
and analytical factors were evaluated to develop a test with 
high sensitivity and specificity, keeping in mind the LOD for 
low (<1%) variant allelic frequency (VAF).
Optimization of pre-analytical parameters such as plasma 
separation and selection of an isolation method that ensures 
extraction of a sufficient amount of high-quality DNA is criti-
cal. It has been shown that these pre-analytical factors of blood 
sampling and processing can strongly affect DNA yield24  
as well as downstream analysis. The development of 
PlasmaMonitorTM included evaluation of plasma separation 
and cfDNA extraction methods to maximize yield of quality 
DNA in a scalable, cost-effective manner. Introduction of an 
additional centrifugation step at 16 000 g for 10 minutes, post 
separation of plasma from whole blood resulted in decreased 
debris. We evaluated four commercial cfDNA extraction kits 
across 35 samples; QIAamp circulating nucleic acid kit 
(Qiagen), NucleoSpin Plasma XS (Macherey-Nagel), ZR 
Serum DNA kit (ZYMO Research), and the NEXTPrep-Mag 
cfDNA isolation kit (Bioo Scientific) (Figure 3A). Based on 
the yield, scalability, turnaround time for processing, and cost 
effectiveness, we opted for the NEXTPrep-Mag cfDNA isola-
tion kit.
Current cfDNA extraction methods yield modest quantities 
of nucleic acid content, emphasizing the importance of sensitive 
and accurate quantification and qualification of cfDNA in the 
molecular sequencing process. Although we realize that a bioana-
lyzer analysis to assess fragment size and quality is widely 
accepted to be the norm, we evaluated and validated the use of a 
modified Human Genomic DNA (HGD) QC Assay for quanti-
fication and qualification of the extracted cfDNA to enable effec-
tive downstream processing, taking into consideration DNA 
integrity index (DIN). To be able to establish this method as a 
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Figure 2. PlasmaMonitor™ panel design, content, and criteria for inclusion. (A) Lists the 14 genes on the panel with specific hotspots across each gene; 
(B) outlines the coverage of the different variants across various cancer types; (C) represents the percentage coverage of panel across certain tumor 
types, using the number of samples mutated with those variants on our panel in a specific gene for that tumor type; (D) schematic for the logic that went 
into picking gene content; and (E) lists the criteria considered to determine actionability of a gene/variant.
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Figure 3. (Continued)
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Figure 3. PlasmaMonitor™ pre-analytical and technical considerations. (A) Comparison of four commercial cfDNA extraction kits for yield; (B) 
quantification and qualification of the extracted cfDNA using a custom Human Genomic DNA qC Assay; (C) comparison data demonstrating that using 
our custom quality approach provides more robust quantification data in comparison with the standard qubit assay; (D) pre-analytical validation steps 
including sensitivity and limit of detection (LOD), inter-assay reproducibility, intra-assay reproducibility, and specificity and accuracy; (E) post-sequencing 
validation steps including sensitivity and LOD, inter-assay reproducibility, intra-assay reproducibility, and specificity and accuracy.
QC step in our process, we performed a comparative evaluation 
of a Qubit Fluorometric 2.0 Assay vs a HGD QC Assay (Figure 
3B). Cell-free DIN is measured as the ratio of long-to-short 
DNA fragments.28 cfDNA from apoptotic cells is uniformly 
truncated into 180-200 bp fragments, whereas cfDNA from 
necrotic tumor cells varies in length, leading to elevation of larger 
fragment DNA.29 Our results clearly demonstrated that using 
our custom HGD quality control approach provides more robust 
quantification of cfDNA in comparison with the Qubit assay. 
The method is also capable of generating a quality metric absent 
from the Qubit approach to assess for the presence of high 
molecular weight DNA contamination. When used to prepare a 
subset of samples for NGS, these quantity and quality measures 
produced libraries that passed clinical quality sequencing metrics 
(Figure 3C). By running qPCR for both 129 and 305 bp, we are 
more accurately able to discern quality of the sample through 
looking at the portion of sample that is greater than 129 and 305 
bps. As cfDNA exhibits a narrow size distribution around 160-
180 bp, 129-bp qPCR results accurately detect the total quantity 
of cfDNA and high molecular weight gDNA. 305-bp qPCR 
results indicate only the presence of high molecular weight cel-
lular gDNA contamination.
Validation for the PlasmaMonitorTM for clinical use 
included sequencing of 21 molecularly uncharacterized tumor 
samples, and 14 known controls under established metrics and 
was completed in 5 phases: (1) sample processing for validation 
parameter determination; (2) LOD, sensitivity, specificity, and 
accuracy; (3) inter-assay concordance; (4) intra-assay concord-
ance; and (5) clinical validity in terms of interpretation and 
reporting of variants identified, per recommended guide-
lines30,31 (Figure 3D and E). The final clinical protocol was 
developed using an input of 10 ng of cfDNA quantified and 
qualified by a custom qPCR assay to establish DIN values, 
where ⩽0.8 was considered optimal (Table 2). Using samples 
containing variants with known allele frequencies and ddPCR-
based confirmation of novel variants identified by our assay, we 
established the assay’s LOD.
We used the SeraSeq ctDNA reference materials which con-
tain a list of 11 hotspot cancer mutations at known allele fre-
quency (1.2%, 0.5%, and 0.1%) in the following genes: AKT1, 
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BRAF, EGFR, KRAS, PIK3CA, and TP53. In addition, we used 
three clinical samples with ddPCR-validated hotspot variants at 
0.6%, 1%, and 5% allele frequency. Using these samples and the 
corresponding SeraSeq circulating tumor wild-type control, we 
designed a titration experiment to obtain samples with allele fre-
quencies of 0.2%, 0.3%, 0.4%, 0.6%, 0.7%, 0.8%, 0.9%, and 1%. 
At each allele frequency from 0.1% to 1.2%, we then evaluated 
the assay’s ability to correctly identify known variants (sensitiv-
ity). At allele frequency of ⩾0.9%, we achieved a sensitivity of 
~96% and we therefore deduced 0.9% as our assay’s LOD. At 
this LOD, sensitivity, specificity, and accuracy were found to be 
96.6%, 100%, and 98%, respectively (Table 3). As the validation 
results indicate, the PlasmaMonitorTM is a well designed genetic 
test that is able to provide a comprehensive actionable report to 
the patient (Supplemental Figure 1).
Current Guidelines (Recommendations) for ctDNA 
Testing
A joint review assessing ctDNA testing in oncology was 
recently released by the American Society of Clinical Oncology 
(ASCO) and the College of American Pathologists (CAP).32 
This review surveyed the current status of ctDNA analysis in 
the field and provides a framework for the future development 
of ctDNA tests. The guidelines outline four areas of signifi-
cance, namely, pre-analytical challenges, analytical validity, 
interpretation and reporting of variants, and the clinical 
validity and clinical utility (Table 4) to be specifically consid-
ered during the development of ctDNA assays.32
Receipt and processing of clinical samples has to follow the 
same established process (stringency and quality control) for 
each sample from beginning (accessioning) to end (sending the 
report out to the physician). Pre-analytical considerations33 
include optimal blood sampling, handling protocols, and long-
term plasma and cfDNA storage which need to be considered 
in parallel with test validation criteria32 (Figure 3D and E). 
Specimen handling from collection through shipping, trans-
portation, and storage needs to be performed with the utmost 
care and adherence to regulations including chain of custody, 
while addressing sample stability since these aspects are critical 
and impact downstream processing.
Shipping and storage conditions of the plasma samples can 
cause varying concern as stability can decrease in a few days. 
To offset these variables, clinical testing laboratories including 
JAX provide a requisition form that includes acceptable condi-
tions of samples to ensure that the collecting site is aware of 
the requirements prior to sample collection. It has been shown 
that improper shipping and storage conditions may lead to 
damage of DNA nucleases resulting in genomic DNA con-
tamination. An additional aspect of specimen collection is the 
blood draw site, as no data are currently available comparing 
blood acquisition from other sites compared with peripheral 
veins, and phlebotomists should follow the tube manufactur-
er’s instructions for use.32
Plasma is stable when stored at −80°C for long-term stor-
age. While using plasma, attention should be paid to the type 
of tubes used for blood collection. Stability of cfDNA can be 
increased using EDTA since it inhibits nuclease (DNAse I) 
activity; heparin, however, has been shown to impact down-
stream processing of plasma including yield of cfDNA 
obtained. Condition of specimen is also equally important, par-
ticularly in terms of hemolysis, which can spuriously increase 
DNA yields. However, blood storage tubes incorporating 
EDTA, have a bigger incidence rate of genomic DNA (gDNA) 
contamination if blood is stored in them for more than 7 days. 
gDNA increased ~2-fold on day 14 in blood collection tubes 
(BCT) tubes (Streck) as opposed to a 456-fold increase in 
K3EDTA tubes,34 making them the preferred tubes for speci-
men collection for liquid biopsies. Upon receipt of the blood 
sample at JAX, to ensure proper sample processing and down-
stream analysis of the PlasmaMonitorTM, plasma is immedi-
ately isolated and stored in the −80°C freezer to maintain 
stability and avoid degradation and contamination of DNA.
Analytical validity is essential and needs to be clearly estab-
lished for all clinical grade assays. Currently, the ASCO/CAP 
consensus for cfDNA assays concludes that there is a discord-
ance between solid tumor sequencing and liquid biopsy testing 
and therefore suggests that solid tumor evaluation be followed 
by a liquid biopsy assay for concordance and recommend the 
confirmation of variants identified in liquid biopsy assays by 
orthogonal methods.32 A critical aspect of the difference 
Table 3. PlasmaMonitor™ analytical performance characteristics and 
results.
PERFORMANCE 
CHARACTERISTICS
RESULTS
Accuracy 98%
Sensitivity 96%
Specificity 100%
Precision (repeatability 
and reproducibility)
100%
LOD 0.9% SNVs and indels
Reportable range Variants detected/not detected 
above the LOD within the region 
of interest. No regions of low 
coverage observed
Table 2. Established pre-analytical and sequencing quality control cut-
offs for PlasmaMonitorTM.
TECHNICAL PARAMETER ESTABLISHED METRIC
Extraction (ng) ⩾10
DNA integrity score ⩽0.8
Final library concentration (ng/µL) ⩾0.5
Mean target coverage ⩾20 000
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Table 4. Summary of ASCO/CAP (Merker, Oxnard and Compton, 2018) considerations for liquid biopsy assays in the clinic.
CONSIDERATIONS PAPER CONSENSUS EXAMPLES
Pre-analytical •  Plasma is suggested to be the optimal specimen type for analysis of circulating tumor DNA (ctDNA).
•  Specimen collection, handling variables, storage condition and time, and patient-related biological factors need to be 
studied further to assess the affect these variables play in ctDNA analysis.
•  Sample processing should be started immediately upon receipt, no later than 48 hours post collection, if stored in cell 
stabilization tubes.
Analytical validity •  There is discordance between the results obtained from solid tumor profiling and liquid biopsy, and supports 
confirmation of variants obtained from evaluation of solid tumors.
• Defining assay limit of detection (LOD) is of utmost importance:
    LOD may vary across the differing genes on a panel and the target specimen type therefore needs to be taken into 
consideration when defining the LOD.
    More cross panel testing is needed to set stricter LOD standards for ctDNA assays to function as reliable standalone assays.
Interpretation and 
reporting variants
•  Incorporation of any available clinical information as well as information from tumor analysis, particularly with the 
identification of an actionable somatic variant in a ctDNA assay, is important to provide appropriate therapeutic options.
• The fraction of ctDNA present in total cell-free DNA in plasma varies significantly between different patients:
    Variant allele frequency of potentially actionable variants called from ctDNA assays need further study.
• Caution is needed when reporting whether a somatic variant is or is not identified by a ctDNA assay:
   Should be conveyed with understanding of possible discordance if compared with a solid tissue test.
Clinical validity • There is only emerging evidence of clinical validity in the application of liquid biospy assays.
•  Concerns still remain regarding clinical validity of liquid biopsies including quantifying tumor origin and minimum 
residual disease.
Clinical utility • Currently there is no evidence of clinical utility with this application as a stand alone test.
•  Acknowledges that there is evidence that may support initiation of a targeted therapy when a ctDNA assay identifies a 
relevant genomic marker that is concordant with results from tumor tissue.
between solid tumor and plasma-based evaluation is the LOD 
and VAF. Defining LOD for an assay is of utmost importance, 
for ctDNA assays in particular, the LOD will be lower than 
those of solid tumor genotyping assays due the small amounts 
of DNA being shed from the tumor.
Similar to FoundationOne® Liquid panel (Table 1), which 
can act as a stand-alone panel or accompany the FoundationOne 
CDx™ FDA-approved solid tumor panel, the PlasmaMonitorTM 
is established to be used for the evaluation of both solid tumor as 
well as plasma samples. The PlasmaMonitorTM has a LOD of 
0.9%, which complements our solid tumor assay and allows for 
variant detection as well as confirmation, if needed. We do note 
that there are other liquid biopsy tests currently available such as 
the Guardant360 which can detect very low-frequency variants 
(0.01%), in contrast to the PlasmaMonitorTM. For those variants 
identified in our solid tumor evaluation that are not present in 
the PlasmaMonitorTM, we have developed and validated a 
ddPCR assay. In line with the shortcomings acknowledged by the 
ASCO/CAP consensus panel, we approached the concern of the 
liquid biopsy test being less reliable when compared with solid 
tumor testing, in terms of the high false-positive rate, by orthog-
onally confirming mutations detected by PlasmaMonitorTM 
using ddPCR, prior to reporting detected gene variants. We have 
also restricted analysis to only three nucleotide positions within 
a given hotspot for effective variant detection. False-negative 
results still remain a challenge and continued optimization 
efforts are ongoing to ensure that the PlasmaMonitorTM can 
accurately act as a confirmation assay to deliver the most accurate 
information to the patients we serve. With regard to perfor-
mance of monitoring setting across a subset of clinical samples in 
different time points, we predict and expect that samples regard-
less of time points pass all set QC thresholds for the assay.
The ASCO/CAP review also raises a concern regarding the 
issue of discerning between analytical and clinical validity of 
liquid biopsies. Clinical validity including quantifying tumor 
origin and minimum residual disease leads the article to con-
clude that there is only emerging evidence of clinical validity in 
this application.32 For the PlasmaMonitorTM, our intent would 
be to monitor the detection of variants being directly targeted 
for therapy or the emergence of well-established resistance 
mutations in the patient. Our validation included appropriate 
dilution experiments to stratify detection along a variety of 
ranges and the operational LOD cut-off was chosen above 
theoretical LOD to minimize false-positive results (Figure 
3D). We agree that there are serious limitations, both technical 
and interpretive with the analytical and clinical validity. We 
therefore make zero claims or recommendations regarding 
such relationships, rather, only focusing on them as limitations 
of the assay.
In addition to clinical validity, clinical utility is yet to be 
demonstrated for the evaluation of cfDNA to monitor disease. 
To combat the absence of clinical utility on its own, physicians 
receiving results from our PlasmaMonitorTM have access to a 
multidisciplinary genomic tumor board to discuss the utility of 
the reported results (Supplemental Figure 1) on a case-by-case 
basis thus providing a method of clinical utility for our patients. 
For the reasons above, we believe we have employed the assay 
as responsibly as can be done with current research/knowledge/
evidence while addressing the needs and demands of a diverse 
patient and physician population.
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Challenges and Limitations of Liquid Biopsy Assays
Although liquid biopsy has the potential to be an effective 
assay in the detection of clinically relevant variants, monitoring 
the progression of cancer via evaluating exosomes, CTCs or 
cfDNA, can be challenging due to multiple factors including 
but not limited to tumor stage, tumor type, tumor heterogene-
ity, and tissue of origin, necessitating the need for high sensitiv-
ity and specificity and increased robustness of current 
technologies. Because cfDNA is a mix of normal DNA as well 
as non-mutated tumor DNA in addition to tumor DNA, sepa-
rating out enough ctDNA can prove to be a challenge depend-
ing on tumor type and stage.
Allelic frequencies and tumor heterogeneity contribute to 
the false-negative rate. In early-stage tumors especially, 
genomic alterations have been known to be present at very low 
variant allele frequency (VAF) which increases the sensitivity 
and the specificity35 needed for the assay to detect these vari-
ants.36 ctDNA used for genomic variant genotyping represents 
an extremely small fraction of the tumor, in some cases only 
less than 0.01%.37 In parallel, CTCs in early-stage tumors 
commonly occur at extremely low frequencies, making detec-
tion and recovery of the individual cells a burdensome process. 
Detection of CTCs requires a greater volume of blood from 
the patient or highly sensitive and specific analytic methods 
with complex enrichment steps to receive optimal results.12,38,39 
CTCs and cfDNA both when targeted, sequenced, and molec-
ularly characterized might only represent a subpopulation of 
the tumor in the intra-tumor heterogeneity landscape.12 
Aiming to capturing the full heterogeneity of the tumor with 
ctDNA presents the possibility of the presence of DNA from 
normal cells. This leaves room for misinterpretation of the 
tumor because of the background presence of leukocytes and 
the overlap they may have with cancer cells for the genes of 
interest.40 Specimen quality, short half-life of CTCs, and circu-
lating nucleic acids as well impact the final results. The 
PlasmaMonitorTM was developed to follow mutations detected 
in paired solid tumor/plasma samples at low VAF and LOD, 
with the aim to reduce false-negative results; however, stage of 
cancer and tumor heterogeneity could yet contribute to the 
false-negative calls of the assay.
Discussion and Conclusions
In conclusion, liquid biopsy has the advantage of being a 
minimally invasive or non-invasive quick method for the 
detection and analysis of circulating biomarkers, enabling us 
to evaluate a patient at multiple time points during disease 
management. However, given the absence of clinical utility 
and the need for highly sensitive robust technologies to bet-
ter address the false-positive and false-negative rates, the 
liquid biopsy assays are still in their infancy, leaving the tis-
sue biopsy as the superior method of targetable mutation 
identification across a majority of different tumor types. 
The JAX PlasmaMonitorTM provides detection of 84 
hotspot SNVs and indels across 14 clinically actionable 
genes to provide relevant clinical information to both the 
treating physician and the patient, post-solid tumor testing, 
as a way to follow known mutations and monitor disease. 
Given the promise of this area of precision medicine, there 
is clearly a focused effort in driving the current technologies 
to address this unmet need of the patient, with the goal to 
make liquid biopsy a surrogate to traditional methods of 
tumor profiling to play a significant role in the early detec-
tion, prognostication, and therapy guidance.
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